Purpose of this Study
If you choose to join this study, you will complete up to 10 study visits and 2 phone call check-ins over 72 weeks. This study includes:<ul>
<li>Pulmonary function tests (how well your lungs are working)</li>
<li>CT scans of the chest (a special type of imaging that creates 3D X-ray images)</li>
<li>Blood draws</li>
<li>Questionnaires</li></ul>
During the study, you will be randomized (like flipping a coin) to get either:
<li>The study drug (Doxycycline) by mouth twice a day for 72 weeks; OR</li>
<li>A placebo (sugar pill) by mouth twice a day for 72 weeks</li></ul>
<li>Pulmonary function tests (how well your lungs are working)</li>
<li>CT scans of the chest (a special type of imaging that creates 3D X-ray images)</li>
<li>Blood draws</li>
<li>Questionnaires</li></ul>
During the study, you will be randomized (like flipping a coin) to get either:
<li>The study drug (Doxycycline) by mouth twice a day for 72 weeks; OR</li>
<li>A placebo (sugar pill) by mouth twice a day for 72 weeks</li></ul>
Who Can Participate?
Eligibility
Adults ages 30+ who:<ul>
<li>Are living with HIV</li>
<li>Have smoking-related lung disease</li></ul>
For more information about who can join this study, please contact the study team at depth-trial@duke.edu or 919-684-2285.
<li>Are living with HIV</li>
<li>Have smoking-related lung disease</li></ul>
For more information about who can join this study, please contact the study team at depth-trial@duke.edu or 919-684-2285.
Age Range
30-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
We are doing this study to learn more about whether Doxycycline (an antibiotic medication) will help slow the progression of emphysema, or COPD.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
No
Study Details
Full Title
Doxycycline for Emphysema in People Living with HIV (The DEPTH Trial)
Study Website
Principal Investigator
David
Murdoch
Protocol Number
PRO00111021
NCT ID
NCT05382208
Phase
II
Enrollment Status
Open to Enrollment